Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Completed · Phase 2 · Has a placebo group
Conditions studied: Cutaneous Lupus Erythematosus
In brief
The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (formerly GS-9876) in females with moderately-to-severely active cutaneous lupus erythematosus (CLE).
Key facts
- Study ID
- NCT03134222
- Run by
- Gilead Sciences
- People needed
- 47
- Starts
- 2017-05-24
- Expected to finish
- 2019-12-18
- Last updated by the study team
- 2020-06-09
Who can join
Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Wallace Rheumatic Studies Center — Beverly Hills, California, United States
- St. Jude Hospital Yorba Linda DBA Dr. Joseph Heritage Healthcare — Fullerton, California, United States
- Dermatology Research Associates — Los Angeles, California, United States
- Desert Medical Advances — Palm Desert, California, United States
- Medderm Associates — San Diego, California, United States
- Inland Rheumatology Clinical Trials — Upland, California, United States
- Clinical Research of West Florida, Inc. — Clearwater, Florida, United States
- Omega Research Consultants LLC — DeBary, Florida, United States
- DJL Clinical Research, PLLC — Charlotte, North Carolina, United States
- Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States
- Penn State Hershey Medical Center — Hershey, Pennsylvania, United States
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Metroplex Clinical Research Center — Dallas, Texas, United States
- Dermatology Ottawa Research Centre — Ottawa, Canada
- University Health Network (UHN) - Toronto Western Hospital — Toronto, Canada
- K.Papp Clinical Research — Waterloo, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.